292 related articles for article (PubMed ID: 15914616)
21. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits.
Akaishi T; Kurashima H; Odani-Kawabata N; Ishida N; Nakamura M
J Ocul Pharmacol Ther; 2010 Apr; 26(2):181-6. PubMed ID: 20334534
[TBL] [Abstract][Full Text] [Related]
22. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
Sutton A; Gilvarry A; Ropo A
J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
[TBL] [Abstract][Full Text] [Related]
23. Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma.
Ishibashi S; Hirose N; Tawara A; Kubota T
J Glaucoma; 2006 Oct; 15(5):354-7. PubMed ID: 16988595
[TBL] [Abstract][Full Text] [Related]
24. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
25. Reduction of intraocular pressure in mouse eyes treated with latanoprost.
Aihara M; Lindsey JD; Weinreb RN
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):146-50. PubMed ID: 11773025
[TBL] [Abstract][Full Text] [Related]
26. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
[TBL] [Abstract][Full Text] [Related]
27. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
28. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
29. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
[TBL] [Abstract][Full Text] [Related]
30. Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurements.
Nordmann JP; Berdeaux G
Clin Ther; 2007 Aug; 29(8):1751-60; discussion 1750. PubMed ID: 17919556
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.
Lim KS; Nau CB; O'Byrne MM; Hodge DO; Toris CB; McLaren JW; Johnson DH
Ophthalmology; 2008 May; 115(5):790-795.e4. PubMed ID: 18452763
[TBL] [Abstract][Full Text] [Related]
32. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
[TBL] [Abstract][Full Text] [Related]
34. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients.
Konstas AG; Kozobolis VP; Katsimpris IE; Boboridis K; Koukoula S; Jenkins JN; Stewart WC
Ophthalmology; 2007 Apr; 114(4):653-7. PubMed ID: 17197028
[TBL] [Abstract][Full Text] [Related]
36. A comparison of intraocular pressure-lowering effect of prostaglandin F2 -alpha analogues, latanoprost, and unoprostone isopropyl.
Kobayashi H; Kobayashi K; Okinami S
J Glaucoma; 2001 Dec; 10(6):487-92. PubMed ID: 11740220
[TBL] [Abstract][Full Text] [Related]
37. Local effect of topical FP-receptor agonists on retinal vessels of the ipsilateral posterior retina in normal rabbit eyes.
Ohashi M; Mayama C; Ishi K; Araie M
Clin Exp Ophthalmol; 2008 Nov; 36(8):767-74. PubMed ID: 19128383
[TBL] [Abstract][Full Text] [Related]
38. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma.
Saito M; Takano R; Shirato S
Am J Ophthalmol; 2001 Oct; 132(4):485-9. PubMed ID: 11589867
[TBL] [Abstract][Full Text] [Related]
39. Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.
Wang RF; Gagliuso DJ; Mittag TW; Podos SM
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4143-7. PubMed ID: 17724199
[TBL] [Abstract][Full Text] [Related]
40. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension.
Hepsen IF; Ozkaya E
Eye (Lond); 2007 Apr; 21(4):453-8. PubMed ID: 16543930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
